ReviewEXCLI journal2026
Nanotechnology-driven delivery of dexamethasone for arthritis: The role of liposomes.
Review in EXCLI journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arthritis is one of the most prevalent chronic musculoskeletal disorders worldwide, affecting more than 300 million individuals and representing a leading cause of pain, disability, and reduced quality of life. The global burden of osteoarthritis and rheumatoid arthritis continues to rise due to population aging, sedentary lifestyles, and increasing metabolic comorbidities. Liposomal drug carriers hold great promise in maximizing dexamethasone's therapeutic utility while minimizing its first-pass effect and systemic toxicity. Due to their biocompatibility, slow-release capability, and potential for target-specific delivery, liposomes enable localized drug sequestration within inflamed joints through both passive and active targeting mechanisms. This review aims to analyze the pharmacological action of dexamethasone in arthritis in conjunction with the advantages inherent to liposomal formulations, as well as recent advancements in liposome design, such as stimuli-responsive and theranostic liposomes. Despite their great promise, limitations, including drug leakage, immunogenicity, and regulatory hurdles, remain major impediments to their clinical use. Future directions indicate promise for personalized, image-directed liposomal therapies in a paradigm shift for arthritis treatment. Overall, liposomal dexamethasone represents a major breakthrough in the safe design of target-specific, effective anti-inflammatory therapies for arthritis. See also the graphical abstract(Fig. 1).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.